APREA THERAPEUTICS INC (APRE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.50-1.96%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · APRE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
APRE — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued
Dated 2026-07-23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 23, 2026, Aprea Therapeutics, Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that, while the Company has not yet regained compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), Nasdaq has dete…
Why it matters: Faster enrollment can help the company gather trial data on time. A slower pace may delay the study.
Watch forThe company reports enrollment of at least 6 patients per month by the end of Q4 2026.
Also watch forThe company reports enrollment below 6 patients per month by the end of Q4 2026, or fewer than 10 active trial sites.
Why it matters: New trial results can show if the early tumor responses last and if treatment remains tolerable.
Watch forAt the Q4 2026 update, at least one partial response is still confirmed. No new severe side effects from treatment are reported.
Also watch forThe update reports no confirmed partial responses and no loss of earlier responses. It reports no new severe side effects from treatment.
Why it matters: Finishing the planned study work can show more clearly how safe and active the treatment is in the target cancers.
Watch forA company update says dose increases and the planned expansion to at least 50 patients are complete by Q2 2027.
Also watch forBy the end of Q2 2027, dose escalation or enrollment in the planned expansion is still incomplete. Or the company delays the timeline.
Why it matters: The company reported $41.2 million in cash and a runway into Q1 2028. Higher costs or new funding needs could weaken that position.
Worry ifA later report cuts the cash runway to before Q1 2028 or shows cash below the level needed to fund planned APR-1051 trials.
Less concerning ifA later report keeps the runway at least through Q1 2028 and funds the stated trial plans without a new share sale.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$262 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $863 loss on $10,000 · 8.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,723 loss on $10,000 · 67.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The company paused ATRN-119 alone and is exploring combination studies. A named study would show the next step for the program.
Supportive ifA company release or trial record names an ATRN-119 combination and a partner site. It also names a study start or first patient enrolled.
Worry ifThe company says it has no active plan for an ATRN-119 combination. Or it reports no named study by its next two quarterly updates.